《大行報告》大摩料華潤醫藥(03320.HK)未來15日股價將升 評級「增持」看7元
摩根士丹利發表技術研究報告,預料華潤醫藥(03320.HK)未來15日股價將上升,發生此機率料80%以上,予「增持」評級,目標價7元。
大摩指,本年至今華潤醫藥累升26%,表現跑贏MSCI中國醫療保健指數和恆生指數,但在過去三周內股價回調11%,可能是由於宏觀經濟因素和獲利回吐。考慮到上半年穩固的盈利前景,預測收入和利潤按年分別增長16%和18%,並認為在8月25日公布中期業績及之後時間,是一個技術性的買入機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.